Supplemental $50,000 NIH TABA funding awarded to AlphaThera to support scaled commercialization of Site-specific Antibody Labeling Technology

AlphaThera has been awarded the TABA (Technical & Business Assistance) Fund as supplemental funding to their $1.58M NIH SIBR Phase II Grant Award for the project titled “Tools for the site-specific labeling and immobilization of antibodies for immunoassays”. Read more about this SBIR Phase II grant here. This funding will offer support focused primarily on scaling the commercialization effort of the oYo-Link® Antibody labeling reagents

AlphaThera has identified three key activities to focus on with the assistance of TABA funding that will fuel continued commercialization of their site-specific antibody labeling products, branded as oYo-Link® Antibody labeling reagents. The prime activities include continued multi-channel marketing, strategic partner development, and IP protection.

With growing international interest, AlphaThera has already established distribution agreements with strategic partners, including Funakoshi Co., Ltd. for distribution in Japan and with Quartzy to distribute in North America. Read more here. The TABA funding will expedite continued expansion to distribution of the oYo-Link® products to other countries.